Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00004908 · ClinicalTrials.gov registry record · Phase 2

Radiation Therapy and Cyclophosphamide Plus Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma

A Phase 2 study, sponsored by Northwestern University.

Completed
Registry status
Phase 2
Development phase

NCT00004908: Completed Phase 2 study, sponsored by Northwestern University.

NCT00004908 is a Phase 2 study that has completed, run by Northwestern University. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00004908, a Phase 2 study, has completed, sponsored by Northwestern University.

COMPLETED
Registry status
Phase 2
Development phase

Study Summary

RATIONALE: Radiation therapy uses high-energy x-rays to damage cancer cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Peripheral stem cell transplantation may allow doctors to give higher doses of chemotherapy drugs and kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of radiation therapy and cyclophosphamide plus peripheral stem cell transplantation in treating patients who have recurrent or refractory Hodgkin's disease or non-Hodgkin's lymphoma.

Interventions

  • DRUG cyclophosphamide
  • RADIATION radiation therapy
  • PROCEDURE peripheral blood stem cell transplantation

Trial Details

FieldValue
Start Date 1999-11
Est. Completion 2002-06
Phase Phase 2
Northwestern University

1,209 total trials

What the finished NCT00004908 record still lists

NCT00004908 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.

The record links to 0 conditions, and to 3 interventions - of which cyclophosphamide is the first listed.

NCT00004908 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00004908 about?

NCT00004908 is a clinical study titled "Radiation Therapy and Cyclophosphamide Plus Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma". RATIONALE: Radiation therapy uses high-energy x-rays to damage cancer cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Peripheral stem cell transplantation may allow doctors to give higher doses of chemotherapy drugs and kill more c...

What is the current status of trial NCT00004908?

This trial is currently completed. It is a Phase 2 study. The study started on 1999-11. Estimated completion is 2002-06.

What interventions are being tested in trial NCT00004908?

The interventions under investigation include: cyclophosphamide (DRUG), radiation therapy (RADIATION), peripheral blood stem cell transplantation (PROCEDURE).

Who is sponsoring clinical trial NCT00004908?

This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00004908, the US trial registry maintained by the National Library of Medicine. NCT00004908 (unsized enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.